1-20 of 28
Michael J. Morris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies

Michael C. Haffner, Michael J. Morris, Chien-Kuang C. Ding, Erolcan Sayar, Rohit Mehra, Brian Robinson, Lawrence D. True, Martin Gleave, Tamara L. Lotan, Rahul Aggarwal, Jiaoti Huang, Massimo Loda, Peter S. Nelson, Mark A. Rubin, Himisha Beltran
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (3): 466–478.
https://doi.org/10.1158/1078-0432.CCR-24-2061
Published: 03 February 2025
View articletitled, Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Open the PDF for Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies in another window
Includes: Supplementary data
Journal Articles

Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer

Konrad H. Stopsack, Joseph Vijai, Michael Conry, Jacob E. Berchuck, Yelena Kemel, Samantha E. Vasselman, Dory A. Freeman, Gwo-Shu M. Lee, Diana Mandelker, David B. Solit, Michael J. Morris, Kathryn L. Penney, Wassim Abida, Kenneth Offit, Lorelei A. Mucci, Philip W. Kantoff, Mark M. Pomerantz
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 122–129.
https://doi.org/10.1158/1078-0432.CCR-24-2483
Published: 06 January 2025
View articletitled, Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer
Open the PDF for Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

Jeffrey L. Jensen, Olivia Bobek, Irenaeus C. C. Chan, Brian C. Miller, David W. Hillman, Glenn Heller, Todd Druley, Andrew J. Armstrong, Michael J. Morris, Matthew I. Milowsky, Himisha Beltran, Kelly L. Bolton, Catherine C. Coombs
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4910–4919.
https://doi.org/10.1158/1078-0432.CCR-24-0803
Published: 01 November 2024
View articletitled, Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Open the PDF for Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) in another window
Includes: Supplementary data
Journal Articles

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer

Andrew T. Lenis, Vignesh Ravichandran, Samantha Brown, Syed M. Alam, Andrew Katims, Hong Truong, Peter A. Reisz, Samantha Vasselman, Barbara Nweji, Karen A. Autio, Michael J. Morris, Susan F. Slovin, Dana Rathkopf, Daniel Danila, Sungmin Woo, Hebert A. Vargas, Vincent P. Laudone, Behfar Ehdaie, Victor Reuter, Maria Arcila, Michael F. Berger, Agnes Viale, Howard I. Scher, Nikolaus Schultz, Anuradha Gopalan, Mark T.A. Donoghue, Irina Ostrovnaya, Konrad H. Stopsack, David B. Solit, Wassim Abida
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3894–3903.
https://doi.org/10.1158/1078-0432.CCR-23-3403
Published: 03 September 2024
View articletitled, Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Open the PDF for Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Wassim Abida, Andrew W. Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R. Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Rongda Xu, Jian Wang, Shravani Barkund, Aleksandr Pankov, Amber Wang, Melissa R. Junttila, Pratik S. Multani, Anneleen Daemen, Edna Chow Maneval, Christopher J. Logothetis, Michael J. Morris
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1111–1120.
https://doi.org/10.1158/1078-0432.CCR-23-3508
Published: 15 March 2024
View articletitled, Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Open the PDF for Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide in another window
Includes: Supplementary data
Journal Articles

The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, Bastien Nguyen, Konrad H. Stopsack, Christoph Kreitzer, Sai Harisha Rajanala, Romina Ghale, Ying Z. Mazzu, Naga Vara Kishore Pillarsetty, Gwo-Shu Mary Lee, Howard I. Scher, Michael J. Morris, Tiffany Traina, Pedram Razavi, Wassim Abida, Jeremy C. Durack, Stephen B. Solomon, Matthew G. Vander Heiden, Lorelei A. Mucci, Andreas G. Wibmer, Nikolaus Schultz, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3603–3617.
https://doi.org/10.1158/1078-0432.CCR-21-4272
Published: 15 August 2022
View articletitled, The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Open the PDF for The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Andrew B. Nixon, Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, Herbert I. Hurwitz, Phillip G. Febbo, Brian I. Rini, Himisha Beltran, Eric J. Small, Michael J. Morris, Daniel J. George
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2771–2778.
https://doi.org/10.1158/1078-0432.CCR-21-2386
Published: 01 July 2022
View articletitled, Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Open the PDF for Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance) in another window
Includes: Supplementary data
Journal Articles

Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Konrad H. Stopsack, Subhiksha Nandakumar, Kanika Arora, Bastien Nguyen, Samantha E. Vasselman, Barbara Nweji, Sean M. McBride, Michael J. Morris, Dana E. Rathkopf, Susan F. Slovin, Daniel C. Danila, Karen A. Autio, Howard I. Scher, Lorelei A. Mucci, David B. Solit, Mithat Gönen, Yu Chen, Michael F. Berger, Nikolaus Schultz, Wassim Abida, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 318–326.
https://doi.org/10.1158/1078-0432.CCR-21-2577
Published: 15 January 2022
View articletitled, Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Open the PDF for Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

Lawrence Fong, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E. Kadel, III, Kobe C. Yuen, Asim Datye, Andrew J. Armstrong, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4746–4756.
https://doi.org/10.1158/1078-0432.CCR-21-0063
Published: 01 September 2021
View articletitled, A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3674–3682.
https://doi.org/10.1158/1078-0432.CCR-20-4573
Published: 01 July 2021
View articletitled, Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Open the PDF for Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study in another window
Includes: Supplementary data
Journal Articles

Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

Goutam Chakraborty, Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa, Mohammad Atiq, Lina E. Jehane, Konrad H. Stopsack, Gwo-Shu Mary Lee, Wassim Abida, Michael J. Morris, Lorelei A. Mucci, Daniel Danila, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1792–1806.
https://doi.org/10.1158/1078-0432.CCR-20-2483
Published: 15 March 2021
View articletitled, Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Open the PDF for Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors in another window
Includes: Supplementary data
Journal Articles

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Karen A. Autio, Christopher A. Klebanoff, David Schaer, John Sae Wook Kauh, Susan F. Slovin, Matthew Adamow, Victoria S. Blinder, Manisha Brahmachary, Michelle Carlsen, Elizabeth Comen, Daniel C. Danila, Thompson N. Doman, Jeremy C. Durack, Josef J. Fox, Jill S. Gluskin, David M. Hoffman, Suhyun Kang, Praneet Kang, Jonathan Landa, Philomena F. McAndrew, Shanu Modi, Michael J. Morris, Ruslan Novosiadly, Dana E. Rathkopf, Rachel Sanford, Sonya C. Chapman, Courtney M. Tate, Danni Yu, Phillip Wong, Heather L. McArthur
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5609–5620.
https://doi.org/10.1158/1078-0432.CCR-20-0855
Published: 02 November 2020
View articletitled, Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Open the PDF for Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer

Konrad H. Stopsack, Subhiksha Nandakumar, Andreas G. Wibmer, Samuel Haywood, Emily S. Weg, Ethan S. Barnett, Chloe J. Kim, Emily A. Carbone, Samantha E. Vasselman, Bastien Nguyen, Melanie A. Hullings, Howard I. Scher, Michael J. Morris, David B. Solit, Nikolaus Schultz, Philip W. Kantoff, Wassim Abida
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3230–3238.
https://doi.org/10.1158/1078-0432.CCR-20-0168
Published: 01 July 2020
View articletitled, Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Open the PDF for Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN

Abdallah Flaifel, Wanling Xie, David A. Braun, Miriam Ficial, Ziad Bakouny, Amin H. Nassar, Rebecca B. Jennings, Bernard Escudier, Daniel J. George, Robert J. Motzer, Michael J. Morris, Thomas Powles, Evelyn Wang, Ying Huang, Gordon J. Freeman, Toni K. Choueiri, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6080–6088.
https://doi.org/10.1158/1078-0432.CCR-19-1135
Published: 15 October 2019
View articletitled, PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Open the PDF for PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN in another window
Includes: Supplementary data
Journal Articles

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Daniel L. Hertz, Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William Kevin Kelly, Jai Patel, Susan Halabi, Yoichi Furukawa, Heather E. Wheeler, Alexander B. Sibley, Cameron Lassiter, Lois Weisman, Dorothy Watson, Stefanie D. Krens, Flora Mulkey, Cynthia L. Renn, Eric J. Small, Phillip G. Febbo, Ivo Shterev, Deanna L. Kroetz, Paula N. Friedman, John F. Mahoney, Michael A. Carducci, Michael J. Kelley, Yusuke Nakamura, Michiaki Kubo, Susan G. Dorsey, M. Eileen Dolan, Michael J. Morris, Mark J. Ratain, Howard L. McLeod
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4890–4900.
https://doi.org/10.1158/1078-0432.CCR-15-2823
Published: 02 October 2016
View articletitled, Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Open the PDF for Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer

Michael J. Morris, Dana E. Rathkopf, William Novotny, Jacqueline A. Gibbons, Amy C. Peterson, Zakaria Khondker, Taoufik Ouatas, Howard I. Scher, Mark T. Fleming
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (15): 3774–3781.
https://doi.org/10.1158/1078-0432.CCR-15-2638
Published: 31 July 2016
View articletitled, Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Neeta Pandit-Taskar, Joseph A. O'Donoghue, Jeremy C. Durack, Serge K. Lyashchenko, Sarah M. Cheal, Volkan Beylergil, Robert A. Lefkowitz, Jorge A. Carrasquillo, Danny F. Martinez, Alex Mak Fung, Stephen B. Solomon, Mithat Gönen, Glenn Heller, Massimo Loda, David M. Nanus, Scott T. Tagawa, Jarett L. Feldman, Joseph R. Osborne, Jason S. Lewis, Victor E. Reuter, Wolfgang A. Weber, Neil H. Bander, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5277–5285.
https://doi.org/10.1158/1078-0432.CCR-15-0552
Published: 30 November 2015
View articletitled, A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Open the PDF for A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer

Dana Rathkopf, Glenn Liu, Michael A. Carducci, Mario A. Eisenberger, Aseem Anand, Michael J. Morris, Susan F. Slovin, Yasutsuna Sasaki, Shunji Takahashi, Seiichiro Ozono, Nga Kit Eliza Fung, Shinta Cheng, Jinping Gan, Marco Gottardis, Mary T. Obermeier, Jyotsna Reddy, Steven Zhang, Blisse J. Vakkalagadda, Leila Alland, George Wilding, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 880–887.
https://doi.org/10.1158/1078-0432.CCR-10-2955
Published: 15 February 2011
View articletitled, Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Open the PDF for Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer in another window
Journal Articles

Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer

Gustavo S.P. Meirelles, Heiko Schöder, Gregory C. Ravizzini, Mithat Gönen, Josef J. Fox, John Humm, Michael J. Morris, Howard I. Scher, Steven M. Larson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6093–6099.
https://doi.org/10.1158/1078-0432.CCR-10-1357
Published: 16 December 2010
View articletitled, Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer
Open the PDF for Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer in another window
Journal Articles

Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer

David J. Gallagher, Mia M. Gaudet, Prodipto Pal, Tomas Kirchhoff, Lisa Balistreri, Kinjal Vora, Jasmine Bhatia, Zsofia Stadler, Samson W. Fine, Victor Reuter, Michael Zelefsky, Michael J. Morris, Howard I. Scher, Robert J. Klein, Larry Norton, James A. Eastham, Peter T. Scardino, Mark E. Robson, Kenneth Offit
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 2115–2121.
https://doi.org/10.1158/1078-0432.CCR-09-2871
Published: 31 March 2010
View articletitled, Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Open the PDF for Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer in another window